# A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

> **NCT02752048** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** TAS-205
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02752048
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-10-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752048, "A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02752048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*